Quadrivalent Virus-Like Particle (VLP) Vaccine Emerging Drug Insights and Market Forecasts, 2019-2022 and 2023-2032
December 14, 2023 10:03 ET
|
Research and Markets
Dublin, Dec. 14, 2023 (GLOBE NEWSWIRE) -- The "Quadrivalent VLP vaccine Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.This report...
FLUARIX Research Report 2023: A Vaccine Indicated for Active Immunization to Prevent Disease Caused by Influenza A Subtype Viruses and Type B Viruses - Drug Insights and Market Forecasts 2019-2032
December 12, 2023 05:13 ET
|
Research and Markets
Dublin, Dec. 12, 2023 (GLOBE NEWSWIRE) -- The "FLUARIX QUADRIVALENT Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.This report provides...
FLUMIST Research Report 2023: The Most Widely Available Quadrivalent Live Attenuated Influenza Vaccine - Drug Insights and Market Forecasts 2019-2032
December 12, 2023 05:08 ET
|
Research and Markets
Dublin, Dec. 12, 2023 (GLOBE NEWSWIRE) -- The "FLUMIST QUADRIVALENT Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.This report provides...
FLUAD QUADRIVALENT Drug Insight and Market Forecasts, 2019-2032: Focus on 6MM - United States, Germany, France, Italy, Spain and United Kingdom
December 12, 2023 04:53 ET
|
Research and Markets
Dublin, Dec. 12, 2023 (GLOBE NEWSWIRE) -- The "FLUAD QUADRIVALENT Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.This report provides...
FLUBLOK: A Quadrivalent Influenza Vaccine for Adults Aged 18 and Older - Drug Insights and Market Forecast to 2032
December 12, 2023 04:48 ET
|
Research and Markets
Dublin, Dec. 12, 2023 (GLOBE NEWSWIRE) -- The "FLUBLOK QUADRIVALENT Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.This "FLUBLOK QUADRIVALENT...
Global Respiratory Disease Vaccine Research Report 2023: A $70+ Billion Industry by 2030 - Increasing Prevalence and Growing Focus on Prevention Bolsters Growth
December 12, 2023 03:13 ET
|
Research and Markets
Dublin, Dec. 12, 2023 (GLOBE NEWSWIRE) -- The "Respiratory Disease Vaccine Market Size, Share & Trends Analysis Report By Type (Viral, Bacterial, Combination), By Age Group, By Infection...
Microbial Fermentation Technology Market revenue to hit USD 63 Billion by 2036, says Research Nester
December 06, 2023 06:00 ET
|
Research Nester
New York , Dec. 06, 2023 (GLOBE NEWSWIRE) -- The global microbial fermentation technology market size is expected to expand at 6% CAGR from 2024 to 2036. The market is anticipated to garner a...
VAX-24 Phase 1/2 Adult Proof-of-Concept Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 24-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate
December 04, 2023 18:35 ET
|
Vaxcyte, Inc.
-- In the Study, VAX-24 Demonstrated a Safety and Tolerability Profile Similar to Prevnar 20® (PCV20) at all Doses Studied -- -- All 24 Serotypes of VAX-24 at Conventional 2.2 mcg PCV Dose Met or...
Protein Engineering Market Size to Reach USD 11.22 Billion in 2032 | Emergen Research
December 04, 2023 08:52 ET
|
Emergen Research
Vancouver, Dec. 04, 2023 (GLOBE NEWSWIRE) -- The global Protein Engineering Market is expected to reach USD 11.22 Billion by 2032, according to a new report by Emergen Research. The growth of this...
EBViously Presents Novel In-Vitro Data Demonstrating Potent Infection Prevention of its Vaccine Candidate EBV-001
December 04, 2023 04:00 ET
|
AKAMPION
Presentation at the World Vaccine Congress West Coast2023EBV-001 is designed for the prevention of Epstein-Barr Virus (EBV)-induced diseases via high titers of potent, neutralizing antibodiesNovel...